glp-1 short term use receptor agonists The real GLP-1 cost crisis

Semaglutide carries a warning about potential worsening of diabetic retinopathy, particularly in patients with pre-existing retinopathy and rapid improvement in glucose control

The most frequently reported issues for new patients were nausea, constipation, and GI issues

These rearrangements in the agonist-bound homomeric GluK2 and GluK3 (Meyerson et al., 2016

NAION is a debilitating eye condition that can cause permanent vision loss

Key areas of concern for decision makers and executives include: Continued rapid rates of increased utilization: Treatment guideline recommendations to prefer GLP-1 agonists and GIP/GLP-1 dual agonists over other less expensive diabetic treatments Increase in physicians awareness of obesity as a disease Stronger trust in the long-term effects and safety of GLP-1 receptor agonists Unwavering demand by individuals seeking quick weight loss solutions Additional products seeking approval and entering the market: Over 50 products are currently in clinical development for obesity and/or T2D GLP-1 agonism is being studied in combination with other mechanisms of action including GIP agonism, glucagon agonism, amylin agonism, and PYY agonism Shortages of currently marketed drugs provide opportunity for additional products to successfully enter the marketplace Additional indications for these products are gaining approval: Clinical trials are ongoing for several indications beyond the currently approved obesity and/or T2D uses Examples of therapeutic applications currently under investigation include Parkinsons and Alzheimers diseases, smoking cessation, alcoholism, and MASH The GLP-1 agonist market is rapidly evolving with significant implications for payers

The loading phase is critical for establishing circulating levels of TB-500